Sequential treatment of melanoma patients who progressed on interleukin-2 and dacarbazine by alpha-interferon and dacarbazine--a preliminary report.
alpha-Interferon, 3 x 10(6) U/m2 every other day, and dacarbazine, up to 800 mg/m2 every 3 weeks, were given to nine patients with metastatic malignant melanoma who had progressed on a combination of interleukin-2 and dacarbazine. Partial response was documented in two patients for 9 and 4 months. Responsive sites were the lungs, lymph nodes, liver, and skin. Failure to respond to one biologic response modifier does not predict the response to another modifier.
Merimsky
O
O
Department of Oncology, Ichilov Hospital, Tel Aviv Sourasky Medical Center, Israel.
Inbar
M
M
Shiloni
E
E
Ron
I
I
Chaitchik
S
S
D000328:Adult; D003606:Dacarbazine / Q000008:administration & dosage / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007370:Interferon Type I / Q000008:administration & dosage / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000627:therapeutic use*; D008297:Male; D008545:Melanoma / Q000188:drug therapy / Q000628:therapy*; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy / Q000628:therapy; D011994:Recombinant Proteins
D007155:Immunologic Factors; D007370:Interferon Type I; D007376:Interleukin-2; D011994:Recombinant Proteins; D003606:Dacarbazine